Lethal photosensitization of wound-associated microbes using indocyanine green and near-infrared light

Ghada S Omar, Michael Wilson, Sean P Nair, Ghada S Omar, Michael Wilson, Sean P Nair

Abstract

Background: The increase in resistance to antibiotics among disease-causing bacteria necessitates the development of alternative antimicrobial approaches such as the use of light-activated antimicrobial agents (LAAAs). Light of an appropriate wavelength activates the LAAA to produce cytotoxic species which can then cause bacterial cell death via loss of membrane integrity, lipid peroxidation, the inactivation of essential enzymes, and/or exertion of mutagenic effects due to DNA modification. In this study, the effect of the LAAA indocyanine green excited with high or low intensity light (808 nm) from a near-infrared laser (NIR) on the viability of Staphylococcus aureus, Streptococcus pyogenes and Pseudomonas aeruginosa was investigated.

Results: All species were susceptible to killing by the LAAA, the bactericidal effect being dependent on both the concentration of indocyanine green and the light dose. Indocyanine green photosensitization using both high (1.37 W cm(-2)) and low (0.048 W cm(-2)) intensity NIR laser light was able to achieve reductions of 5.6 log10 (>99.99%) and 6.8 log10 (>99.99%) in the viable counts of Staph. aureus and Strep. pyogenes (using starting concentrations of 106-107 CFU ml(-1)). Kills of 99.99% were obtained for P. aeruginosa (initial concentration 108-109 CFU ml(-1)) photosensitized by the high intensity light (1.37 W cm(-2)); while a kill of 80% was achieved using low intensity irradiation (0.07 W cm(-2)). The effects of L-tryptophan (a singlet oxygen scavenger) and deuterium oxide (as an enhancer of the life span of singlet oxygen) on the survival of Staph. aureus was also studied. L-tryptophan reduced the proportion of Staph. aureus killed; whereas deuterium oxide increased the proportion killed suggesting that singlet oxygen was involved in the killing of the bacteria.

Conclusion: These findings imply that indocyanine green in combination with light from a near-infrared laser may be an effective means of eradicating bacteria from wounds and burns.

Figures

Figure 1
Figure 1
High intensity lethal photosensitization of Staph. aureus □ and Strep. pyogenes ▨ with 25 μg ml-1 ICG or P. aeruginosa ■ with 200 μg ml-1 ICG. An equal volume of either 50 μg ml-1 (in the case of Staph. aureus and Strep. pyogenes) or 400 μg ml-1 (in the case of P. aeruginosa) ICG (L-S+ and L+S+) or PBS (L-S- and L+S-) was added to each bacterial suspension, samples were left for 10 minutes in the dark and then irradiated at a fluence rate of 1.37 W cm-2 with a light dose of 411 J cm-2 from a NIR 808 nm laser (L+S- and L+S+) or kept in the dark (L-S+ and L-S-).
Figure 2
Figure 2
Lethal photosensitization of Staph. aureus ●, Strep. pyogenes □ with 25,50, 100 and 200 μg ml-1 ICG, and P. aeruginosa ▲ with 25,50, 100, 200 and 250 μg ml-1 ICG. An equal volume of the appropriate ICG concentration (L+S+) was added to each bacterial suspension, samples were left for 10 minutes in the dark and then irradiated at a fluence rate of 1.37 W cm-2 with light dose of 411 J cm-2 from a NIR 808 nm laser.
Figure 3
Figure 3
(A) Lethal photosensitization of Staph. aureus □ and Strep. pyogenes using a final concentration of 25 μg ml-1 ICG. Samples were left for 10 minutes in the dark and then irradiated using a fluence rate of 0.048 W cm-2 for 15 and 30 minutes, corresponding to light doses of 43 & 86 J cm-2 respectively. (B) Lethal photosensitization of P. aeruginosa ■ using a final concentration of 200 μg ml-1 ICG. Samples were left for 10 minutes in the dark and then irradiated using a fluence rate of 0.07 W cm-2 for 35 minutes, corresponding to light dose of 147 J cm-2. L-S- and L+S- were kept in the dark.
Figure 4
Figure 4
High intensity lethal photosensitization of Staph. aureus □, Strep. pyogenes ▨ with 25 μg ml-1 ICG and P. aeruginosa ■ with 200 μg ml-1 ICG. An equal volume of either 50 μg ml-1 (in the case of Staph. aureus and Strep. pyogenes) or 400 μg ml-1 (in the case of P. aeruginosa) ICG (L-S+ and L+S+) or PBS (L-S- and L+S-) was added to each bacterial suspension. Samples were left in the dark for 30 minutes and then (L+S- and L+S+) irradiated at a fluence rate of 1.37 W cm-2 for 1, 3 or 5 minutes with light from a NIR 808 nm laser, corresponding to light doses of 82, 247, or 411 J cm-2 respectively. Samples L-S+ and L-S- were kept in the dark.
Figure 5
Figure 5
Lethal photosensitization of Staph. aureus in 50% horse serum (HS) using 25 □ or 200 ■ μg ml-1 ICG. An equal volume of either 50 or 400 μg ml-1 ICG (L-S+ and L+S+) or PBS (L-S- and L+S-) was added to Staph. aureus suspensions in HS and samples were left for 10 minutes in the dark and then irradiated at a fluence rate of 1.37 W cm-2 and a light dose of 411 J cm-2 using a NIR 808 nm laser (L+S- and L+S+) or kept in the dark (L-S+ and L-S-).
Figure 6
Figure 6
High intensity lethal photosensitization of Staph. aureus (A) suspended in 10 mM L-tryptophan ■ or suspended in H2O and (B), suspended in D2O or suspended in H2O □. In this experiment an ICG concentration of 25 μg ml-1 was used and samples were pre-incubated in the dark for 10 minutes before being irradiated at a fluence rate of 1.37 W cm-2 and light dose of 82 J cm-2.

References

    1. Ansermino M, Hemsley C. Intensive care management and control of infection. BMJ. 2004;329:220–223. doi: 10.1136/bmj.329.7459.220.
    1. Healy B, Freedman A. Infections. BMJ. 2006;332:838–841. doi: 10.1136/bmj.332.7545.838.
    1. Plowman R. The socioeconomic burden of hospital acquired infection. Euro Surveill. 2000;5:49–50.
    1. Cuthbertson BH, Thompson M, Sherry A, Wright MM, Bellingan GJ. Antibiotic-treated infections in intensive care patients in the UK. Anaesthesia. 2004;59:885–890. doi: 10.1111/j.1365-2044.2004.03742.x.
    1. Finch R. Antibiotic resistance – from pathogen to disease surveillance. Clin Microbiol Infect. 2002;8:317–320. doi: 10.1046/j.1469-0691.2002.00436.x.
    1. Ogeer-Gyles JS, Mathews KA, Boerlin P. Nosocomial infections and antimicrobial resistance in critical care medicine. J Vet Emerg Crit Care. 2006;16:1–18. doi: 10.1111/j.1476-4431.2005.00162.x.
    1. Hamblin MR, O'Donnell DA, Murthy N, Rajagopalan K, Michaud N, Sherwood ME, Hasan T. Polycationic photosensitizer conjugates: effects of chain length and Gram classification on the photodynamic inactivation of bacteria. J Antimicrob Chemother. 2002;49:941–951. doi: 10.1093/jac/dkf053.
    1. Embleton ML, Nair SP, Heywood W, Menon DC, Cookson BD, Wilson M. Development of a novel targeting system for lethal photosensitization of antibiotic-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49:3690–3696. doi: 10.1128/AAC.49.9.3690-3696.2005.
    1. Jori G, Fabris C, Soncin M, Ferro S, Coppellotti O, Dei D, Fantetti L, Chiti G, Roncucci G. Photodynamic therapy in the treatment of microbial infections: basic principles and perspective applications. Lasers Surg Med. 2006;38:468–481. doi: 10.1002/lsm.20361.
    1. Lambrechts SA, Demidova TN, Aalders MC, Hasan T, Hamblin MR. Photodynamic therapy for Staphylococcus aureus infected burn wounds in mice. Photochem Photobiol Sci. 2005;4:503–509. doi: 10.1039/b502125a.
    1. Hamblin MR, Hasan T. Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci. 2004;3:436–450. doi: 10.1039/b311900a.
    1. Kintarak S, Nair SP, Speight PM, Whawell SA. A recombinant fragment of the fibronectin-binding protein of Staphylococcus aureus inhibits keratinocyte migration. Arch Dermatol Res. 2004;296:250–257. doi: 10.1007/s00403-004-0515-y.
    1. Bisland SK, Chien C, Wilson BC, Burch S. Pre-clinical in vitro and in vivo studies to examine the potential use of photodynamic therapy in the treatment of osteomyelitis. Photochem Photobiol Sci. 2006;5:31–38. doi: 10.1039/b507082a.
    1. Wilson M, Pratten J. Lethal photosensitisation of Staphylococcus aureus in vitro: effect of growth phase, serum, and pre-irradiation time. Lasers Surg Med. 1995;16:272–276. doi: 10.1002/lsm.1900160309.
    1. Orenstein A, Klein D, Kopolovic J, Winkler E, Malik Z, Keller N, Nitzan Y. The use of porphyrins for eradication of Staphylococcus aureus in burn wound infections. FEMS Immunol Med Microbiol. 1997;19:307–314. doi: 10.1016/S0928-8244(97)00097-7.
    1. Reszka KJ, Denning GM, Britigan BE. Photosensitized oxidation and inactivation of pyocyanin, a virulence factor of Pseudomonas aeruginosa. Photochem Photobiol. 2006;82:466–473. doi: 10.1562/2005-07-29-RA-626.
    1. Nitzan Y, Gutterman M, Malik Z, Ehrenberg B. Inactivation of gram-negative bacteria by photosensitized porphyrins. Photochem Photobiol. 1992;55:89–96. doi: 10.1111/j.1751-1097.1992.tb04213.x.
    1. Minnock A, Vernon DI, Schofield J, Griffiths J, Parish JH, Brown ST. Photoinactivation of bacteria. Use of a cationic water-soluble zinc phthalocyanine to photoinactivate both gram-negative and gram-positive bacteria. J Photochem Photobiol B. 1996;32:159–164. doi: 10.1016/1011-1344(95)07148-2.
    1. Hamblin MR, Zahra T, Contag CH, McManus AT, Hasan T. Optical monitoring and treatment of potentially lethal wound infections in vivo. J Infect Dis. 2003;187:1717–1725. doi: 10.1086/375244.
    1. Hope CK, Wilson M. Induction of lethal photosensitization in biofilms using a confocal scanning laser as the excitation source. J Antimicrob Chemother. 2006;57:1227–1230. doi: 10.1093/jac/dkl096.
    1. Saxena V, Sadoqi M, Shao J. Degradation kinetics of indocyanine green in aqueous solution. J Pharm Sci. 2003;92:2090–2097. doi: 10.1002/jps.10470.
    1. Saxena V, Sadoqi M, Shao J. Polymeric nanoparticulate delivery system for Indocyanine green: biodistribution in healthy mice. Int J Pharm. 2006;308:200–204. doi: 10.1016/j.ijpharm.2005.11.003.
    1. Tuchin VV, Genina EA, Bashkatov AN, Simonenko GV, Odoevskaya OD, Altshuler GB. A pilot study of ICG laser therapy of acne vulgaris: photodynamic and photothermolysis treatment. Lasers Surg Med. 2003;33:296–310. doi: 10.1002/lsm.10211.
    1. Genina EA, Bashkatov AN, Simonenko GV, Odoevskaya OD, Tuchin VV, Altshuler GB. Low-intensity indocyanine-green laser phototherapy of acne vulgaris: pilot study. J Biomed Opt. 2004;9:828–834. doi: 10.1117/1.1756596.
    1. Nouri K, Ballard CJ. Laser therapy for acne. Clin Dermatol. 2006;24:26–32. doi: 10.1016/j.clindermatol.2005.10.020.
    1. Saxena V, Sadoqi M, Shao J. Indocyanine green-loaded biodegradable nanoparticles: preparation, physicochemical characterization and in vitro release. Int J Pharm. 2004;278:293–301. doi: 10.1016/j.ijpharm.2004.03.032.
    1. Malicka J, Gryczynski I, Geddes CD, Lakowicz JR. Metal-enhanced emission from indocyanine green: a new approach to in vivo imaging. J Biomed Opt. 2003;8:472–478. doi: 10.1117/1.1578643.
    1. Tseng WW, Saxton RE, Deganutti A, Liu CD. Infrared laser activation of indocyanine green inhibits growth in human pancreatic cancer. Pancreas. 2003;27:e42–e45. doi: 10.1097/00006676-200310000-00018.
    1. Baumler W, Abels C, Karrer S, Weiss T, Messmann H, Landthaler M, Szeimies RM. Photo-oxidative killing of human colonic cancer cells using indocyanine green and infrared light. Br J Cancer. 1999;80:360–3. doi: 10.1038/sj.bjc.6690363.
    1. Urbanska K, Romanowska-Dixon B, Matuszak Z, Oszajca J, Nowak-Sliwinsk P, Stochel G. Indocyanine green as a prospective sensitizer for photodynamic therapy of melanomas. Acta Biochim Pol. 2002;49:387–391.
    1. Iriyama A, Uchida S, Yanagi Y, Tamaki Y, Inoue Y, Matsuura K, Kadonosono K, Araie M. Effects of indocyanine green on retinal ganglion cells. Invest Ophthalmol Vis Sci. 2004;45:943–947. doi: 10.1167/iovs.03-1026.
    1. Jackson TL, Hillenkamp J, Knight BC, Zhang JJ, Thomas D, Stanford MR, Marshall J. Safety testing of indocyanine green and trypan blue using retinal pigment epithelium and glial cell cultures. Invest Ophthalmol Vis Sci. 2004;45:2778–2785. doi: 10.1167/iovs.04-0320.
    1. Rezai KA, Farrokh-Siar L, Ernest JT, van Seventer GA. Indocyanine green induces apoptosis in human retinal pigment epithelial cells. Am J Ophthalmol. 2004;137:931–933. doi: 10.1016/j.ajo.2003.11.016.
    1. Skrivanova K, Skorpikova J, Svihalek J, Mornstein V, Janisch R. Photochemical properties of a potential photosensitiser indocyanine green in vitro. J Photochem Photobiol B. 2006;85:150–154. doi: 10.1016/j.jphotobiol.2006.06.004.
    1. Czajka MP, McCuen BW, Cummings TJ, Nguyen H, Stinnett S, Wong F. Effects of indocyanine green on the retina and retinal pigment epithelium in a porcine model of retinal hole. Retina. 2004;24:275–282. doi: 10.1097/00006982-200404000-00014.
    1. Yip HK, Lai TY, So KF, Kwok AK. Retinal ganglion cells toxicity caused by photosensitising effects of intravitreal indocyanine green with illumination in rat eyes. Br J Ophthalmol. 2006;90:99–102. doi: 10.1136/bjo.2005.076042.
    1. Saikia P, Maisch T, Kobuch K, Jackson TL, Baumler W, Szeimies RM, Gabel VP, Hillenkamp J. Safety testing of indocyanine green in an ex vivo porcine retina model. Invest Ophthalmol Vis Sci. 2006;47:4998–5003. doi: 10.1167/iovs.05-1665.
    1. Abels C, Fickweiler S, Weiderer P, Bäumler W, Hofstädter F, Landthaler M, Szeimies RM. Indocyanine green (ICG) and laser irradiation induce photooxidation. Arch Dermatol Res. 2000;292:404–411. doi: 10.1007/s004030000147.
    1. Maisch T, Szeimies RM, Jori G, Abels C. Antibacterial photodynamic therapy in dermatology. Photochem Photobiol Sci. 2004;3:907–917. doi: 10.1039/b407622b.
    1. Jori G, Brown SB. Photosensitized inactivation of microorganisms. Photochem Photobiol Sci. 2004;3:403–405. doi: 10.1039/b311904c.
    1. Malik Z, Ladan H, Nitzan Photodynamic inactivation of Gram negative bacteria: problems and possible solutions. J Photochem Photobiol B: Biol. 1990;5:281–293. doi: 10.1016/1011-1344(90)85044-W.
    1. Nussbaum EL, Lilge L, Mazzulli T. Effects of low-level laser therapy (LLLT) of 810 nm upon in vitro growth of bacteria: relevance of irradiance and radiant exposure. J Clin Laser Med Surg. 2003;21:283–290. doi: 10.1089/104454703322564497.
    1. Nitzan Y, Balzam-Sudakevitz A, Ashkenazi H. Eradication of Acinetobacter baumannii by photosensitized agents in vitro. J Photochem Photobiol B. 1998;42:211–218. doi: 10.1016/S1011-1344(98)00073-6.
    1. Lu WD, Atkins WM. A novel antioxidant role for ligandin behavior of glutathione S-transferases: attenuation of the photodynamic effects of hypericin. Biochemistry. 2004;43:12761–12769. doi: 10.1021/bi049217m.
    1. Lambrechts SA, Aalders MC, Verbraak FD, Lagerberg JW, Dankert JB, Schuitmaker JJ. Effect of albumin on the photodynamic inactivation of microorganisms by a cationic porphyrin. J Photochem Photobiol B. 2005;79:51–57. doi: 10.1016/j.jphotobiol.2004.11.020.
    1. Matheson IB, Etheridge RD, Kratowich NR, Lee J. The quenching of singlet oxygen by amino acids and proteins. Photochem Photobiol. 1975;21:165–171. doi: 10.1111/j.1751-1097.1975.tb06647.x.
    1. Storm FK, Harrison WH, Elliott RS, Morton DL. Normal tissue and solid tumor effects of hyperthermia in animal models and clinical trials. Cancer Res. 1979;39:2245–2251.
    1. Prins JB, Walker NI, Winterford CM, Cameron DP. Apoptosis of human adipocytes in vitro. Biochem Biophys Res Commun. 1994;201:500–507. doi: 10.1006/bbrc.1994.1730.
    1. Henderson BW, Waldow SM, Potter WR, Dougherty TJ. Interaction of photodynamic therapy and hyperthermia: tumor response and cell survival studies after treatment of mice in vivo. Cancer Res. 1985;45:6071–6077.
    1. Altshuler GB, Zenzie HH, Erofeev AV, Smirnov MZ, Anderson RR, Dierickx C. Contact cooling of the skin. Phys Med Biol. 1999;44:1003–1023. doi: 10.1088/0031-9155/44/4/014.
    1. Clayton TH, Harrison PV. Photodynamic therapy for infected leg ulcers. Br J Dermatol. 2007;156:384–385. doi: 10.1111/j.1365-2133.2006.07619.x.
    1. Carvalho Pde T, Marques AP, Reis FA, Belchior AC, Silva IS, Habitante CA, Sussai DA. Photodynamic inactivation of in vitro bacterial cultures from pressure ulcers. Acta Cir Bras. 2006;21:32–35.
    1. Chin WW, Heng PW, Bhuvaneswari R, Lau WK, Olivo M. The potential application of chlorin e6-polyvinylpyrrolidone formulation in photodynamic therapy. Photochem Photobiol Sci. 2006;5:1031–1037. doi: 10.1039/b605772a.
    1. Maisch T. Anti-microbial photodynamic therapy: useful in the future? Lasers Med Sci. 2006
    1. Allison RR, Downie GH, Cuenca R, Hu XH, Childs CJ, Sibata CH. Photosensitizers in clinical PDT. Photodiag Photodyn Ther. 2004;1:27–42. doi: 10.1016/S1572-1000(04)00007-9.
    1. Detty MR, Gibson SL, Wagner SJ. Current clinical and preclinical photosensitizers for use in photodynamic therapy. J Med Chem. 2004;47:3897–3915. doi: 10.1021/jm040074b.

Source: PubMed

3
Subskrybuj